We have located links that may give you full text access.
The prognostic role of 18 F-FDG PET/CT-based response evaluation in children with stage 4 neuroblastoma.
European Radiology 2024 May 17
OBJECTIVES: To evaluate the association between metabolic response on 18 F-FDG PET/CT and long-term survival in children with neuroblastoma (NB).
METHODS: A total of 39 consecutive children with newly diagnosed stage 4 NB undergoing both 18 F-FDG PET/CT imaging at baseline and after chemotherapy were retrospectively analyzed. The associations between metabolic parameters, including SUVmax of the lesion with the most intense 18 F-FDG uptake at baseline (SUVb), after chemotherapy (SUVe), and the percentage change between SUVb and SUVe, and long-term survival were evaluated.
RESULTS: With a median follow-up of 56 months, 22 patients who had achieved complete resolution on PET (no residual 18 F-FDG uptake higher than the surrounding backgrounds) after chemotherapy had superior 5-year overall survival (OS) (73.6% vs. 39.0%, p = 0.044). SUVb > 6.9 indicated significantly poorer 5-year event-free survival (EFS) (12.5% vs. 59.3%, p = 0.005), as did SUVe > 1.2 (18.8% vs. 41.7%, p = 0.041). Children with SUVe > 1.2 had shorter 5-year OS (33.9% vs. 75.0%, p = 0.018). Multivariate analysis identified SUVe > 1.2 as an independent predictor for both EFS [hazard ratio (HR), 3.479, 95% CI, 1.381-8.761, p = 0.008] and OS (HR, 6.948, 95% CI, 1.663-29.025, p = 0.008), while SUVb > 6.9 was a predictor for EFS (HR, 2.889, 95% CI, 1.064-7.842, p = 0.037). Among 11 children with both SUVb > 6.9 and SUVe > 1.2, all experienced disease progression or relapse within 2 years since diagnosis.
CONCLUSION: 18 F-FDG PET/CT could be of useful to evaluate treatment response in children with stage 4 NB.
CLINICAL RELEVANCE STATEMENT: 18 F-FDG PET/CT after chemotherapy exhibits prognostic significance in neuroblastoma and holds potential as an alternative imaging modality for response evaluation, especially in cases with metaiodobenzylguanidine-nonavid or persistent avid disease.
KEY POINTS: The prognostic value of chemotherapy response on 18 F-FDG PET/CT in advanced neuroblastoma is unknown. Higher 18 F-FDG uptake after chemotherapy was associated with worse long-term event-free survival and overall survival. 18 F-FDG PET/CT after chemotherapy holds prognostic significance in children with stage 4 neuroblastoma.
METHODS: A total of 39 consecutive children with newly diagnosed stage 4 NB undergoing both 18 F-FDG PET/CT imaging at baseline and after chemotherapy were retrospectively analyzed. The associations between metabolic parameters, including SUVmax of the lesion with the most intense 18 F-FDG uptake at baseline (SUVb), after chemotherapy (SUVe), and the percentage change between SUVb and SUVe, and long-term survival were evaluated.
RESULTS: With a median follow-up of 56 months, 22 patients who had achieved complete resolution on PET (no residual 18 F-FDG uptake higher than the surrounding backgrounds) after chemotherapy had superior 5-year overall survival (OS) (73.6% vs. 39.0%, p = 0.044). SUVb > 6.9 indicated significantly poorer 5-year event-free survival (EFS) (12.5% vs. 59.3%, p = 0.005), as did SUVe > 1.2 (18.8% vs. 41.7%, p = 0.041). Children with SUVe > 1.2 had shorter 5-year OS (33.9% vs. 75.0%, p = 0.018). Multivariate analysis identified SUVe > 1.2 as an independent predictor for both EFS [hazard ratio (HR), 3.479, 95% CI, 1.381-8.761, p = 0.008] and OS (HR, 6.948, 95% CI, 1.663-29.025, p = 0.008), while SUVb > 6.9 was a predictor for EFS (HR, 2.889, 95% CI, 1.064-7.842, p = 0.037). Among 11 children with both SUVb > 6.9 and SUVe > 1.2, all experienced disease progression or relapse within 2 years since diagnosis.
CONCLUSION: 18 F-FDG PET/CT could be of useful to evaluate treatment response in children with stage 4 NB.
CLINICAL RELEVANCE STATEMENT: 18 F-FDG PET/CT after chemotherapy exhibits prognostic significance in neuroblastoma and holds potential as an alternative imaging modality for response evaluation, especially in cases with metaiodobenzylguanidine-nonavid or persistent avid disease.
KEY POINTS: The prognostic value of chemotherapy response on 18 F-FDG PET/CT in advanced neuroblastoma is unknown. Higher 18 F-FDG uptake after chemotherapy was associated with worse long-term event-free survival and overall survival. 18 F-FDG PET/CT after chemotherapy holds prognostic significance in children with stage 4 neuroblastoma.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices 
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app